Swiss drug maker Roche Holding AG has reported a 9 percent drop in first quarter sales due to the weakness of the U.S. dollar and euro against the franc.
Roche says sales were stable in local currencies.
Its best-selling anti-influenza drug Tamiflu also experienced a sharp drop in orders year-on-year.
Roche said Thursday that sales fell to 11.12 billion Swiss francs ($12.4 billion) from 12.25 billion a year earlier.
The company reports earnings only every six months.